Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 12/20 | 1.00 |
| ▸ | BTK | Q06187 | 1/20 | 0.92 |
| ▸ | AURKA | O14965 | 5/20 | 0.62 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2217640 | 0.96 | BTK (1.00) | SYKBTKAURKAEPHB4 | |
| SCHEMBL29523904 | 0.96 | BTK (1.00) | SYKBTKAURKAEPHB4 | |
| SCHEMBL2217415 | 0.94 | SYK (0.89) | SYKBTKAURKAEPHB4 | |
| SCHEMBL6002791 | 0.93 | BTK (0.89) | SYKBTKAURKAEPHB4 | |
| SCHEMBL4811490 | 0.93 | BTK (0.89) | SYKBTKAURKAEPHB4 | |
| SCHEMBL4816119 | 0.93 | BTK (0.89) | SYKBTKAURKAEPHB4 | |
| SCHEMBL2216718 | 0.93 | BTK (0.89) | SYKBTKAURKAEPHB4 | |
| SCHEMBL2217123 | 0.92 | BTK (0.87) | SYKBTKAURKAEPHB4 | |
| SCHEMBL2218534 | 0.92 | BTK (0.87) | SYKBTKAURKAEPHB4 | |
| SCHEMBL2219062 | 0.92 | BTK (0.90) | SYKBTKAURKAEPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405295-B2 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | CGI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | claimed |
| US-20060183746-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | CGI PHARMACEUTICALS, INC. | 2006-08-17 | — | — | US | claimed |
| US-20050090499-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton's tyrosine kinase by such compounds | GILEAD CONNECTICUT, INC. | 2005-04-28 | — | — | US | claimed |
| WO-2005014599-A1 | IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES AND METHOD OF INHIBITION OF BRUTON’S TYROSINE KINASE BY SUCH COMPOUNDS | CELLULAR GENOMICS, INC. (US) | 2005-02-17 | — | — | WO | claimed |
| US-20110177011-A1 | CERTAIN IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES AND METHOD OF INHIBITION OF BRUTON'S TYROSINE KINASE BY SUCH COMPOUNDS | CURRIE KEVIN S | 2011-07-21 | — | — | US | disclosed |
| US-20110177011-A1 | CERTAIN IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES AND METHOD OF INHIBITION OF BRUTON'S TYROSINE KINASE BY SUCH COMPOUNDS | CURRIE KEVIN S | 2011-07-21 | — | — | US | disclosed |
| US-7405295-B2 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | CGI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405295-B2 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | CGI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405295-B2 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | CGI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20060183746-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | CGI PHARMACEUTICALS, INC. | 2006-08-17 | — | — | US | disclosed |
| US-20050090499-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton's tyrosine kinase by such compounds | GILEAD CONNECTICUT, INC. | 2005-04-28 | — | — | US | disclosed |
| WO-2005014599-A1 | IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES AND METHOD OF INHIBITION OF BRUTON’S TYROSINE KINASE BY SUCH COMPOUNDS | CELLULAR GENOMICS, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090499-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton's tyrosine kinase by such compounds | BTK, SYK, JAK1 | SYK 2/4885BTK 1/4885AURKA 197/4885 |
| US-20110177011-A1 | CERTAIN IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES AND METHOD OF INHIBITION OF BRUTON'S TYROSINE KINASE BY SUCH COMPOUNDS | BTK, SYK, JAK1 | SYK 2/4885BTK 1/4885AURKA 197/4885 |
| US-20060183746-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | BTK, SYK, LCK | SYK 2/4885BTK 1/4885AURKA 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.